Interim President & CEO of Gemphire Therapeutics Inc (NASDAQ:GEMP) Steven R. Ph.d. Gullans bought 71,429 shares of GEMP on 02/08/2018 at an average price of $7 a share. The total cost of this purchase was $500,003.
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition....More>>>
While money managers from Goldman Sachs Group Inc. to UBS Wealth Management still tout investing opportunities in emerging markets, the asset class has one notable critic: Harvard professor Carmen Reinhart.
The Cuban-born economist points to mounting debt loads, weakening terms of trade, rising global interest rates and stalling growth as reasons for concern. In fact, developing nations are....More>>>
Investment company Discovery Capital Management, Llc buys Altaba Inc, II-VI Inc, E*TRADE Financial Corp, Signet Jewelers, IQVIA Holdings Inc, Time Warner Inc, EOG Resources Inc, Devon Energy Corp, Tiffany, PNC Financial Services Group Inc, sells Charter Communications Inc, Sprint Corp, Xilinx Inc, Micron Technology Inc, Peabody Energy Corp during the 3-months ended 2017-12-31, according to the....More>>>
Our Top Pick for speculators is a fully integrated medical marijuana, health care, and cannabinoid-based pharmaceutical company, notes Jimmy Mengel, editor of The Crow’s Nest.
Emblem Corp. (Vancouver: EMC) is licensed by the Government of Canada, which allows it to produce medical cannabis.
It was founded by John H. Stewart, the former President and CEO of Purdue Pharma and....More>>>
The stock market performed well on Tuesday, responding to steady improvement among many companies as earnings season kicked into high gear. Although political issues are likely to remain in the spotlight for some investors for the foreseeable future, many market participants are looking to economic and business issues in driving their investing decisions. Major market benchmarks finished the day....More>>>
I won’t keep you in suspense — Warren Buffett-led Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B) owns 400,000,000 shares of Coca-Cola (NYSE:KO), worth a total of $16.7 billion as of this writing. This translates to a 9.4% stake in the beverage giant, and makes Coca-Cola Buffett’s third-largest stock investment.
The investment has served Buffett and Berkshire’s shareholders....More>>>
The market is filled with stocks. Ever since bond yields went to zero as the Federal Reserve tried to rescue the economy from the mortgage crisis, it has forced people to go further out on the risk curve in order to get the income they had been used to getting from bonds.
Risk is the foremost concern of my stock advisory newsletter, The Liberty Portfolio. Most investors unknowingly take on....More>>>
Mobileye NV (NYSE:MBLY) is a company I’ve liked for a long time, and I’ve been pounding the table on it especially hard since January. It was a stock I wanted all of my subscribers to own, and owning it certainly paid off on Monday when it was announced that Intel Corporation (NASDAQ:INTC) would buy the company for a 34.5% premium over Friday’s closing price.
11 Sales Pitches That Kill Sales
3 Ways Harvey Is Touching the Life and Health Community Now
5 Reasons Genworth’s Would-Be Buyer Could Still Close the Deal
Fidelity Investments reported Thursday that a 65-year-old couple retiring this year can expect an estimated $275,000 in health care and medical expenses throughout retirement.
Fidelity’s annual analysis....More>>>
With Johnson & Johnson (JNJ) bouncing off record highs, BTIG has thrown in the towel on its buy rating. Analyst Dane Leone has downgraded the stock today to neutral from buy.J&J fell 0.63% to a recent $113.52.
Downgrading ahead of the Investor Day next week is a risk, but at this point we are not expecting any major strategic shifts. We remain interested in the long-term JNJ story,....More>>>